Zafgen (NASDAQ:ZFGN) Shares Up 5.5%

Zafgen Inc (NASDAQ:ZFGN) shot up 5.5% during mid-day trading on Tuesday . The stock traded as high as $0.77 and last traded at $0.77, 287,576 shares traded hands during mid-day trading. A decline of 21% from the average session volume of 366,294 shares. The stock had previously closed at $0.73.

Several brokerages have issued reports on ZFGN. Roth Capital cut shares of Zafgen from a “buy” rating to a “neutral” rating in a research report on Friday, September 6th. ValuEngine upgraded shares of Zafgen from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. JMP Securities cut shares of Zafgen from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 5th. Zacks Investment Research reaffirmed a “hold” rating on shares of Zafgen in a research note on Saturday. Finally, Wedbush lowered shares of Zafgen from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $6.00 to $0.78 in a research note on Friday, September 6th. Eight analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $6.05.

The stock’s 50 day moving average price is $0.73 and its 200 day moving average price is $1.46. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.98 and a current ratio of 6.98. The company has a market capitalization of $27.50 million, a P/E ratio of -0.41 and a beta of -0.55.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.06. On average, analysts expect that Zafgen Inc will post -1.15 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. AWM Investment Company Inc. boosted its stake in Zafgen by 32.4% during the second quarter. AWM Investment Company Inc. now owns 1,857,171 shares of the biopharmaceutical company’s stock worth $2,210,000 after acquiring an additional 454,874 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Zafgen by 71.2% during the second quarter. Renaissance Technologies LLC now owns 1,678,300 shares of the biopharmaceutical company’s stock worth $1,997,000 after acquiring an additional 697,724 shares in the last quarter. Citadel Advisors LLC boosted its stake in Zafgen by 2.2% during the second quarter. Citadel Advisors LLC now owns 971,818 shares of the biopharmaceutical company’s stock worth $1,156,000 after acquiring an additional 20,953 shares in the last quarter. Worth Venture Partners LLC bought a new position in Zafgen during the second quarter worth $316,000. Finally, Morgan Stanley boosted its stake in Zafgen by 150.8% during the second quarter. Morgan Stanley now owns 184,606 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 110,989 shares in the last quarter. 80.70% of the stock is currently owned by institutional investors.

Zafgen Company Profile (NASDAQ:ZFGN)

Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.

Read More: Understanding the two types of arbitrage

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit